

	Date/Fecha (salida/handling out)	Esquema	Scheme	round	11/01/2022	
25	lunes 09/01/2023	<b>IQ-179 Inmunoproteínas séricas (Igs. C3, C4, C1qh, C1q, Factor</b>	<b>IQ-179 Immunoproteins (Igs. C3, C4, C1qh, C1q, B Factor, RF v</b>	1 K E1	11/01/2022	
27		<b>IQ-3 IgE específica</b>	<b>IQ-3 Specific IgE (native and recombinant allergens)</b>	1 K E1	11/01/2022	
26		<b>IQ-2 Subclases de IgG</b>	<b>IQ-2 IgG subclasses</b>	1 K25 E1	11/01/2022	
36	martes 17/01/2023	<b>HLA-1A Serología clase I</b>	<b>HLA-1A Serological typing of HLA class I</b>	1 T E2	18/01/2022	
44		<b>HLA-5 Tipaje de baja resolución por DNA (2 dígitos)</b>	<b>HLA-5 Low resolution HLA DNA typing</b>	1 T E2	18/01/2022	
48		<b>HLA-8 Quimerismo</b>	<b>HLA-8 Chimerism</b>	1 T E2	18/01/2022	
51		<b>HLA-11 Tipaje HPA</b>	<b>HLA-11A HPA typing</b>	1 T E2	18/01/2022	
1		lunes 23/01/2023	<b>AU-1 Anticuerpos en hepatopatías v gastropatías</b>	<b>AU-1: Autoantibodies related to hepatic and gastric</b>	1 A E3	25/01/2022
2	<b>AU-2 Anticuerpos antinucleares</b>		<b>AU-2: Antinuclear antibodies - ANAs</b>	1 A E3	25/01/2022	
3	<b>AU-3 Anticuerpos antitiroideos</b>		<b>AU-3: Anti-thyroid antibodies</b>	1 A E3	25/01/2022	
43	lunes 30/01/2023	<b>HLA-4B Detección v Análisis de especificidad de anticuerpos</b>	<b>HLA-4B Detection and specificity of anti HLA antibodies (class I</b>	1 S E4	01/02/2022	
50		<b>HLA-10 Anticuerpos inducidos por heparina</b>	<b>HLA-10 Heparine-induced antibodies</b>	1 S E4	01/02/2022	
52		<b>HLA-12A Anticuerpos anti HPA</b>	<b>HLA-12 Anti HPA antibodies</b>	1 S E4	01/02/2022	
54		<b>HLA-12B Anticuerpos anti HNA</b>	<b>HLA-12 Anti HNA antibodies</b>	1 S E4	01/02/2022	
40		<b>HLA-3 Sueros Prueba cruzada citotoxicidad</b>	<b>HLA-3 Crossmatch sera</b>	1s S E4	01/02/2022	
5	lunes 06/02/2023	<b>AU-6 Anticuerpos antifosfolípidos</b>	<b>AU-6: Anti-phospholipid antibodies</b>	1 A E5	08/02/2022	
7		<b>AU-8 Anticuerpos asociados a enfermedad celiaca</b>	<b>AU-8: Coeliac Disease related antibodies</b>	1 A E5	08/02/2022	
6		<b>AU-7 ANCA's v autoanticuerpos relacionados</b>	<b>AU-7: ANCA's and GBM (related antibodies)</b>	1 B E5	08/02/2022	
28	lunes 13/02/2023	<b>IQ-4 Paraproteínas en suero</b>	<b>IQ-4 Serum paraproteins</b>	1 K36 E6	15/02/2022	
29		<b>IQ-5 Paraproteínas en orina</b>	<b>IQ-5 Urine paraproteins</b>	1 K36 E6	15/02/2022	
25		<b>IQ-179 Inmunoproteínas séricas (Igs. C3, C4, C1qh, C1q, Factor</b>	<b>IQ-179 Immunoproteins (Igs. C3, C4, C1qh, C1q, B Factor, RF v</b>	2 K E6	15/02/2022	
27	27	<b>IQ-3 IgE específica</b>	<b>IQ-3 Specific IgE (native and recombinant allergens)</b>	2 K E6	15/02/2022	
4	lunes 20/02/2023	<b>AU-5 Anticuerpos asociados a diabetes</b>	<b>AU-5: Diabetes related antibodies</b>	1 A25 E8	22/02/2022	
8		<b>AU-9 Anticuerpos anti péptido cíclico citrulinado</b>	<b>AU-9: Anti cyclic citrullinated peptides antibodies</b>	1 A25 E8	22/02/2022	
10		<b>AU-16 Anticuerpos antineuronales</b>	<b>AU-16 Antineuronal antibodies</b>	1 A4 E8	22/02/2022	
1		<b>AU-1 Anticuerpos en hepatopatías v gastropatías</b>	<b>AU-1: Autoantibodies related to hepatic and gastric</b>	2 A E8	22/02/2022	
2		<b>AU-2 Anticuerpos antinucleares</b>	<b>AU-2: Antinuclear antibodies - ANAs</b>	2 A E8	22/02/2022	
3	<b>AU-3 Anticuerpos antitiroideos</b>	<b>AU-3: Anti-thyroid antibodies</b>	2 A E8	22/02/2022		
15	miércoles 23/02/2022	<b>IC-2 Stem cells</b>	<b>IC-2 Stem cells</b>	1 G E7	23/02/2022	
17		<b>IC-48 Fenotipo, diagnóstico v enfermedad mínima residual en</b>	<b>IC-48 Immunophenotype (Leukemia / Lymphoma) and M.R.D.</b>	1 H E9	23/02/2022	
14	martes 28/02/2023	<b>IC-1 Poblaciones linfocitarias</b>	<b>IC-1 Lymphocytes</b>	1 F E10	01/03/2022	
16		<b>IC-3 Leucocitos residuales</b>	<b>IC-3 Residual leukocytes</b>	1 F E10	01/03/2022	
46	martes 07/03/2023	<b>HLA-6 Tipaje de alta resolución por DNA (4 dígitos)</b>	<b>HLA-6 High resolution HLA DNA typing</b>	1 O E11	08/03/2022	
49		<b>HLA-9 Tipaje KIR</b>	<b>HLA-9 KIR Typing</b>	1 O E11	08/03/2022	
53		<b>HLA-11B Tipaje HNA</b>	<b>HLA-11B HNA Typing</b>	1 O E11	08/03/2022	
40	lunes 13/03/2023	<b>HLA-3A Prueba cruzada citotoxicidad</b>	<b>HLA-3A Cytotoxicity Crossmatch</b>	3 X E12	14/03/2022	
41		<b>HLA-3B Prueba cruzada citometría</b>	<b>HLA-3B Cytometry Crossmatch</b>	3 X E12	14/03/2022	
5	martes 14/03/2023	<b>AU-6 Anticuerpos antifosfolípidos</b>	<b>AU-6: Anti-phospholipid antibodies</b>	3 A E12	15/03/2022	
7		<b>AU-8 Anticuerpos asociados a enfermedad celiaca</b>	<b>AU-8: Coeliac Disease related antibodies</b>	3 A E12	15/03/2022	
6		<b>AU-7 ANCA's v autoanticuerpos relacionados</b>	<b>AU-7: ANCA's and GBM (related antibodies)</b>	3 B E12	15/03/2022	
32	martes 21/03/2023	<b>IQ-11 Respuesta a vacunación</b>	<b>IQ-11 Response to vaccination</b>	1 M E13	22/03/2022	
33		<b>IQ-14 Producción de v-IFN en respuesta a patógenos</b>	<b>IQ-14 IFN Production in response to pathogens</b>	1 M E13	22/03/2022	
34		<b>IQ-15 Monitorización de tratamiento anti TNFα</b>	<b>IQ-15 Anti TNF therapy monitoring</b>	1 M E13	22/03/2022	
37	martes 18/04/2023	<b>HLA-2A B27</b>	<b>HLA-2A HLA-B27</b>	1 N E14	29/03/2022	
38		<b>HLA-2B B57:01</b>	<b>HLA-2B HLA*B57:01</b>	1 N E14	29/03/2022	
39		<b>HLA-2C DQ2/DQ8</b>	<b>HLA-2C Coeliac disease related HLA</b>	1 N E14	29/03/2022	
9	martes 25/04/2023	<b>AU-14 Anticuerpos v tipaje GSTT1 (antes HLA14A v HLA14B)</b>	<b>AU-14 GSTT1 (antibodies and allele 1)</b>	1 B25 E16	26/04/2022	
11		<b>AU-17 Anticuerpos anti receptor de fosfolipasa A2</b>	<b>AU-17 Anti Phospholipase A2 receptor antibodies</b>	1 B25 E16	26/04/2022	
12		<b>AU-18 Calprotectina</b>	<b>AU-18 Calprotectin</b>	1 B25 E16	26/04/2022	
13		<b>AU-22 Casos Autoinmunidad (Imágenes IFI)</b>	<b>AU-22 Autoimmunity Cases (IFI Images)</b>	1 B25 E16	26/04/2022	
5		<b>AU-6 Anticuerpos antifosfolípidos</b>	<b>AU-6: Anti-phospholipid antibodies</b>	2 A E16	26/04/2022	
7	<b>AU-8 Anticuerpos asociados a enfermedad celiaca</b>	<b>AU-8: Coeliac Disease related antibodies</b>	2 A E16	26/04/2022		
6	<b>AU-7 ANCA's v autoanticuerpos relacionados</b>	<b>AU-7: ANCA's and GBM (related antibodies)</b>	2 B E16	26/04/2022		
20	miércoles 17/05/2023	<b>IC-7 Molecular leucemias</b>	<b>IC-7 Molecular diagnosis of Leukemia</b>	1 J E18	11/05/2022	
24		<b>IC-11 repertorio T</b>	<b>IC-11 T repertoire</b>	1 J E18	11/05/2022	
18	lunes 22/05/2023	<b>IC-5 Función linfocitaria</b>	<b>IC-5 Lymphocyte function</b>	1 I E17	09/05/2022	
19		<b>IC-6 Función Innata</b>	<b>IC-6 Innate function</b>	1 I E17	09/05/2022	
1	martes 16/05/2023	<b>AU-1 Anticuerpos en hepatopatías v gastropatías</b>	<b>AU-1: Autoantibodies related to hepatic and gastric</b>	3 A E19	17/05/2022	
2		<b>AU-2 Anticuerpos antinucleares</b>	<b>AU-2: Antinuclear antibodies - ANAs</b>	3 A E19	17/05/2022	
3		<b>AU-3 Anticuerpos antitiroideos</b>	<b>AU-3: Anti-thyroid antibodies</b>	3 A E19	17/05/2022	
25	lunes 29/05/2023	<b>IQ-179 Inmunoproteínas séricas (Igs. C3, C4, C1qh, C1q, Factor</b>	<b>IQ-179 Immunoproteins (Igs. C3, C4, C1qh, C1q, B Factor, RF v</b>	3 K E20	24/05/2022	
27		<b>IQ-3 IgE específica</b>	<b>IQ-3 Specific IgE (native and recombinant allergens)</b>	3 K E20	24/05/2022	
23		miércoles 31/05/2023	<b>IC-10 Linfocitos PD1</b>	<b>IC-10 PD1 Lymphocytes</b>	1 H E20	24/05/2022
22	<b>IC-9 Monitorización terapia anti CD20 (Rituximab)</b>		<b>IC-9 Anti-CD20 therapy (rituximab) monitoring</b>	1 K E20	24/05/2022	
30	miércoles 07/06/2023		<b>IQ-6 Bandas oligoclonales</b>	<b>IQ-6 Oligoclonal Bands</b>	1 L E21	07/06/2022
31		<b>IQ-8 Complemento funcional</b>	<b>IQ-8 Functional complement</b>	1 L E21	07/06/2022	
35		<b>IQ-17 Citocinas (CD25s, IL6, IL8, antiguo IQ-16 )</b>	<b>IQ-17 Cytokines (IL6, IL8, CD25s)</b>	1 L E21	07/06/2022	
17		miércoles 14/06/2023	<b>IC-48 Fenotipo, diagnóstico v enfermedad mínima residual en</b>	<b>IC-48 Immunophenotype (Leukemia / Lymphoma) and M.R.D.</b>	2 H E22	15/06/2022
20		miércoles 21/06/2023	<b>IC-7 Molecular leucemias</b>	<b>IC-7 Molecular diagnosis of Leukemia</b>	2 J E23	22/06/2022
1	lunes 26/06/2023	<b>AU-1 Anticuerpos en hepatopatías v gastropatías</b>	<b>AU-1: Autoantibodies related to hepatic and gastric</b>	4 A E24	28/06/2022	
2		<b>AU-2 Anticuerpos antinucleares</b>	<b>AU-2: Antinuclear antibodies - ANAs</b>	4 A E24	28/06/2022	
3		<b>AU-3 Anticuerpos antitiroideos</b>	<b>AU-3: Anti-thyroid antibodies</b>	4 A E24	28/06/2022	
25		<b>IQ-179 Inmunoproteínas séricas (Igs. C3, C4, C1qh, C1q, Factor</b>	<b>IQ-179 Immunoproteins (Igs. C3, C4, C1qh, C1q, B Factor, RF v</b>	4 K E24	28/06/2022	
27		<b>IQ-3 IgE específica</b>	<b>IQ-3 Specific IgE (native and recombinant allergens)</b>	4 K E24	28/06/2022	
5	lunes 04/09/2023	<b>AU-6 Anticuerpos antifosfolípidos</b>	<b>AU-6: Anti-phospholipid antibodies</b>	4 A E26	13/09/2022	
7		<b>AU-8 Anticuerpos asociados a enfermedad celiaca</b>	<b>AU-8: Coeliac Disease related antibodies</b>	4 A E26	13/09/2022	
6		<b>AU-7 ANCA's v autoanticuerpos relacionados</b>	<b>AU-7: ANCA's and GBM (related antibodies)</b>	4 B E26	13/09/2022	
43	lunes 11/09/2023	<b>HLA-4B Detección v Análisis de especificidad de anticuerpos</b>	<b>HLA-4B Detection and specificity of anti HLA antibodies (class I</b>	2 S E25	06/09/2022	
50		<b>HLA-10 Anticuerpos inducidos por heparina</b>	<b>HLA-10 Heparine-induced antibodies</b>	2 S E25	06/09/2022	
54		<b>HLA-12B Anticuerpos anti HNA</b>	<b>HLA-12 Anti HNA antibodies</b>	2 S E25	06/09/2022	
26		lunes 18/09/2023	<b>IQ-2 Subclases de IgG</b>	<b>IQ-2 IgG subclasses</b>	2 K25 E28	27/09/2022
28			<b>IQ-4 Paraproteínas en suero</b>	<b>IQ-4 Serum paraproteins</b>	2 K36 E28	27/09/2022
29	<b>IQ-5 Paraproteínas en orina</b>		<b>IQ-5 Urine paraproteins</b>	2 K36 E28	27/09/2022	
25	<b>IQ-179 Inmunoproteínas séricas (Igs. C3, C4, C1qh, C1q, Factor</b>		<b>IQ-179 Immunoproteins (Igs. C3, C4, C1qh, C1q, B Factor, RF v</b>	5 K E28	27/09/2022	
27	<b>IQ-3 IgE específica</b>		<b>IQ-3 Specific IgE (native and recombinant allergens)</b>	5 K E28	27/09/2022	
36	martes 19/09/2023	<b>HLA-1A Serología clase I</b>	<b>HLA-1A Serological typing of HLA class I</b>	2 T E27	20/09/2022	
44		<b>HLA-5 Tipaje de baja resolución por DNA (2 dígitos)</b>	<b>HLA-5 Low resolution HLA DNA typing</b>	2 T E27	20/09/2022	
48		<b>HLA-8 Quimerismo</b>	<b>HLA-8 Chimerism</b>	2 T E27	20/09/2022	
51		<b>HLA-11 Tipaje HPA</b>	<b>HLA-11A HPA typing</b>	2 T E27	20/09/2022	
14		martes 03/10/2023	<b>IC-1 Poblaciones linfocitarias</b>	<b>IC-1 Lymphocytes</b>	2 F E29	04/10/2022
16	<b>IC-3 Leucocitos residuales</b>		<b>IC-3 Residual leukocytes</b>	2 F E29	04/10/2022	
46	martes 17/10/2023	<b>HLA-6 Tipaje de alta resolución por DNA (4 dígitos)</b>	<b>HLA-6 High resolution HLA DNA typing</b>	2 O E30	18/10/2022	
49		<b>HLA-9 Tipaje KIR</b>	<b>HLA-9 KIR Typing</b>	2 O E30	18/10/2022	
53		<b>HLA-11B Tipaje HNA</b>	<b>HLA-11B HNA Typing</b>	2 O E30	18/10/2022	
4	lunes 23/10/2023	<b>AU-5 Anticuerpos asociados a diabetes</b>	<b>AU-5: Diabetes related antibodies</b>	2 A25 E31	25/10/2022	
8		<b>AU-9 Anticuerpos anti péptido cíclico citrulinado</b>	<b>AU-9: Anti cyclic citrullinated peptides antibodies</b>	2 A25 E31	25/10/2022	
1		<b>AU-1 Anticuerpos en hepatopatías v gastropatías</b>	<b>AU-1: Autoantibodies related to hepatic and gastric</b>	5 A E31	25/10/2022	
2		<b>AU-2 Anticuerpos antinucleares</b>	<b>AU-2: Antinuclear antibodies - ANAs</b>	5 A E31	25/10/2022	
3		<b>AU-3 Anticuerpos antitiroideos</b>	<b>AU-3: Anti-thyroid antibodies</b>	5 A E31	25/10/2022	
15	jueves 26/10/2023	<b>IC-2 Stem cells</b>	<b>IC-2 Stem cells</b>	2 G E32	26/10/2022	
40		lunes 06/11/2023	<b>HLA-3A Prueba cruzada citotoxicidad</b>	<b>HLA-3A Cytotoxicity Crossmatch</b>	3 X E33	07/11/2022
41	<b>HLA-3B Prueba cruzada citometría</b>		<b>HLA-3B Cytometry Crossmatch</b>	3 X E33	07/11/2022	
32	martes 07/11/2023	<b>IQ-11 Respuesta a vacunación</b>	<b>IQ-11 Response to vaccination</b>	2 M E32	08/11/2022	
33		<b>IQ-14 Producción de v-IFN en respuesta a patógenos</b>	<b>IQ-14 IFN Production in response to pathogens</b>	2 M E32	08/11/2022	
34		<b>IQ-15 Monitorización de tratamiento anti TNFα</b>	<b>IQ-15 Anti TNF therapy monitoring</b>	2 M E32	08/11/2022	
25	lunes 13/11/2023	<b>IQ-179 Inmunoproteínas séricas (Igs. C3, C4, C1qh, C1q, Factor</b>	<b>IQ-179 Immunoproteins (Igs. C3, C4, C1qh, C1q, B Factor, RF v</b>	6 K E333	08/11/2022	
10		<b>IQ-3 IgE específica</b>	<b>IQ-3 Specific IgE (native and recombinant allergens)</b>	6 K E333	08/11/2022	
9		lunes 13/11/2023	<b>AU-16 Anticuerpos antineuronales</b>	<b>AU-16 Antineuronal antibodies</b>	2 A4 E34	15/11/2022
11	<b>AU-14 Anticuerpos v tipaje GSTT1 (antes HLA14A v HLA14B)</b>		<b>AU-14 GSTT1 (antibodies and allele 1)</b>	2 B25 E34	15/11/2022	
5	<b>AU-6 Anticuerpos antifosfolípidos</b>		<b>AU-6: Anti-phospholipid antibodies</b>	5 A E34	15/11/2022	
7	<b>AU-8 Anticuerpos asociados a enfermedad celiaca</b>		<b>AU-8: Coeliac Disease related antibodies</b>	5 A E34	15/11/2022	
6	<b>AU-7 ANCA's v autoanticuerpos relacionados</b>		<b>AU-7: ANCA's and GBM (related antibodies)</b>	5 B E34	15/11/2022	
13	viernes 17/11/2023	<b>AU-22 Casos Autoinmunidad (Imágenes IFI)</b>	<b>AU-22 Autoimmunity Cases (IFI Images)</b>	2 E E355	23/11/2022	
37		martes 21/11/2023	<b>HLA-2A B27</b>	<b>HLA-2A HLA-B27</b>	2 N E35	22/11/2022
38	<b>HLA-2B B57:01</b>		<b>HLA-2B HLA*B57:01</b>	2 N E35	22/11/2022	
39	<b>HLA-2C DQ2/DQ8</b>		<b>HLA-2C Coeliac disease related HLA</b>	2 N E35	22/11/2022	
18	lunes 27/11/2023	<b>IC-5 Función linfocitaria</b>	<b>IC-5 Lymphocyte function</b>	2 I E37	28/11/2022	
19		<b>IC-6 Función Innata</b>	<b>IC-6 Innate function</b>	2 I E37	28/11/2022	
12	martes 28/11/2023	<b>AU-18 Calprotectina</b>	<b>AU-18 Calprotectin</b>	2 D E36	29/11/2022	
17		miércoles 29/11/2023	<b>IC-48 Fenotipo, diagnóstico v enfermedad mínima residual en</b>	<b>IC-48 Immunophenotype (Leukemia / Lymphoma) and M.R.D.</b>	3 H E388	14/12/2022
30	miércoles 12/12/2023		<b>IQ-6 Bandas oligoclonales</b>	<b>IQ-6 Oligoclonal Bands</b>	2 L E38	14/12/2022
31			<b>IQ-8 Complemento funcional</b>	<b>IQ-8 Functional complement</b>	2 L E38	14/12/2022
35		<b>IQ-17 Citocinas (CD25s, IL6, IL8, antiguo IQ-16 )</b>	<b>IQ-17 Cytokines (IL6, IL8, CD25s)</b>	2 L E38	14/12/2022	
22	13/12/2023	<b>IC-9 Monitorización terapia anti CD20 (Rituximab)</b>	<b>IC-9 Anti-CD20 therapy (rituximab) monitoring</b>	2 K E39	20/12/2022	
1		lunes 18/12/2023	<b>AU-1 Anticuerpos en hepatopatías v gastropatías</b>	<b>AU-1: Autoantibodies related to hepatic and gastric</b>	6 A E38	14/12/2022
2	<b>AU-2 Anticuerpos antinucleares</b>		<b>AU-2: Antinuclear antibodies - ANAs</b>	6 A E38	14/12/2022	
3	<b>AU-3 Anticuerpos antitiroideos</b>		<b>AU-3: Anti-thyroid antibodies</b>	6 A E38	14/12/2022	
5	<b>AU-6 Anticuerpos antifosfolípidos</b>		<b>AU-6: Anti-phospholipid antibodies</b>	6 A E38	14/12/2022	
7	<b>AU-8 Anticuerpos asociados a enfermedad celiaca</b>		<b>AU-8: Coeliac Disease related antibodies</b>	6 A E38	14/12/2022	
6	<b>AU-7 ANCA's v autoanticuerpos relacionados</b>		<b>AU-7: ANCA's and GBM (related antibodies)</b>	6 B E38	14/12/2022	
23	martes 19/12/2023	<b>IC-10 Linfocitos PD1</b>	<b>IC-10 PD1 Lymphocytes</b>	2 H E39	20/12/2022	
24		<b>IC-11 repertorio</b>				